Grünenthal On Hunt For Asia Partner As Pain Killer Hits Phase III Endpoints
Executive Summary
Grünenthal’s novel pain killer has succeeded in a Phase III trial in cancer pain and now the company wants to find a partner for Asian markets, to complement its deal last year with Depomed for North America.
You may also be interested in...
Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Antibe Speeds Hydrogen Sulfide-Releasing NSAID Development
Canada’s Antibe Therapeutics is accelerating the early-stage clinical development of new molecules that depend on the cytoprotective and signaling properties of minute amounts of hydrogen sulfide to have a potent anti-inflammatory and analgesic effect.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.